T Khawaja, M Kajova, I Levonen, J P Pietilä, H Välimaa, J Paajanen, S H Pakkanen, A Patjas, R Montonen, S Miettinen, J Virtanen, T Smura, T Sironen, R Fagerlund, H Ugurlu, R Iheozor-Ejiofor, K Saksela, T Vahlberg, A Ranki, A Vierikko, J Ihalainen, O Vapalahti, A Kantele
INTRODUCTION: Convalescent plasma (CP) emerged as potential treatment for COVID-19 early in the pandemic. While efficacy in hospitalised patients has been lacklustre, CP may be beneficial at the first stages of disease. Despite multiple new variants emerging, no trials have involved analyses on variant-specific antibody titres of CP. METHODS: We recruited hospitalised COVID-19 patients within 10 days of symptom onset and, employing a double-blinded approach, randomised them to receive 200 ml convalescent plasma with high (HCP) or low (LCP) neutralising antibody (NAb) titre against the ancestral strain (Wuhan-like variant) or placebo in 1:1:1 ratio...
March 21, 2024: Infectious Diseases